Analyser av Ortoma

Ortoma: Unexpected CEO change - Redeye

Redeye comments on the announcement that the current CEO has left.

Redeye • 18 Nov 07:22

Ortoma Q3’2024: Positive outlook and finances in focus - Redeye

Redeye makes some revisions based on the Q3 report.

Redeye • 04 Nov 07:27

Ortoma Q3’24: Positive cash flow and strong outlook - Redeye

Redeye provides a short comment on Ortoma’s Q3 report this morning.

Redeye • 31 Oct 10:58

Ortoma: DePuy agreement yielding results - Redeye

Redeye comments on the published order of SEK 31m for OTS™ Hip stemming from the distribution agreement signed with DePuy in September last ...

Redeye • 01 Aug 07:39

Ortoma: Creating a good foundation for growth - Redeye

Redeye makes minor revisions based on the Q2 report.

Redeye • 19 Jul 08:46

Ortoma Q2’24: Building for the future - Redeye

Redeye provides a short comment on Ortoma’s Q2 report this morning.

Redeye • 18 Jul 09:07

Ortoma: Heading in the right direction - Redeye

Redeye makes minor revisions based on the Q1 report.

Redeye • 24 May 07:36

Ortoma Q1’24: Continued progress and 510(k) approval - Redeye

Redeye provides a short comment on Ortoma’s Q1 report this morning.

Redeye • 23 May 09:09

Ortoma: US market approval for OTS™ Hip - Redeye

Redeye is pleased that Ortoma has received the 510(K) approval from the US FDA regarding the OTS™ Hip.

Redeye • 12 Mar 09:25

Ortoma Q4’23: A very exciting year for Ortoma - Redeye

Redeye makes minor revisions based on the Q4 report.

Redeye • 21 Feb 08:02

Ortoma Q4’23: First product sales - Redeye

Redeye provides a short comment on this morning’s Q4 report from Ortoma.

Redeye • 20 Feb 09:53

Ortoma: Outcome of the TO 2B announced - Redeye

Redeye comments on the outcome of the TO 2B announcement published today.

Redeye • 29 Nov 2023 12:58

Ortoma: Leveraging the positive outcome of OTS™ in Japan - Redeye

Redeye is encouraged by the news that Ortoma continues to be active in the Japanese market and leverage the existing agreement with Johnson ...

Redeye • 21 Nov 2023 11:55

Ortoma: First milestone payment from DePuy Synthes - Redeye

Redeye is positively surprised that Ortoma has already received the first milestone payment from DePuy.

Redeye • 02 Nov 2023 09:26

Ortoma: Following the set path - Redeye

Redeye makes minor revisions based on the Q3 report.

Redeye • 27 Oct 2023 08:52

Ortoma Q3’23: Initial impressions – continued strong progress - Redeye

Redeye provides a short comment on this morning’s Q3 report from Ortoma.

Redeye • 26 Oct 2023 10:12

Ortoma: A game changer - Redeye

Redeye ups its near-term sales estimates for Ortoma following its USD8.

Redeye • 26 Sep 2023 09:17

Ortoma: Global development and distribution agreement with Depuy Synthes - Redeye

Redeye comments on Ortoma’s agreement with DePuy Synthes.

Redeye • 20 Sep 2023 09:40

Ortoma Q2 2023: Ignition engaged - Redeye

Redeye leaves its comments on Ortoma following its Q2 2023 report.

Redeye • 23 Aug 2023 11:23

Ortoma: Preplanning for success - Redeye

Redeye initiates coverage of Ortoma, a Swedish medtech company in early stage commercialisation with its Ortoma Treatment Solution (OTS™), h...

Redeye • 14 Aug 2023 07:50

Börskollen

För dig med koll på börsen